Qatar Medical Devices Market Report 2026: HMC Procurement, Sidra Medicine, and Commercial Intelligence

The Qatar medical devices market is estimated at USD 400–460 million in 2026, growing at approximately 7.5% CAGR through 2030. Hamad Medical Corporation (HMC) dominates procurement, accounting for roughly 75% of total device spend. Sidra Medicine — Qatar's women and children's specialty hospital — is a growing high-value account particularly for pediatric and maternal care devices. Qatar's post-FIFA World Cup healthcare infrastructure investment continues to drive capacity expansion.

Hamad Medical Corporation operates centralized procurement for its network of 14 hospitals, including Hamad General Hospital, Heart Hospital, National Center for Cancer Care and Research, and the Neurological and Orthopedic Hospital. HMC issues framework agreements and individual tenders by device category, typically on annual cycles. MOPH Qatar registration is required for all devices. HMC's procurement committee conducts clinical evaluation alongside price assessment — differentiated clinical evidence carries more weight than in Kuwait CMS tenders.

The fastest-growing Qatar medical device segments are: oncology equipment (Qatar's National Center for Cancer Care and Research expansion), cardiovascular devices (Qatar Heart Hospital is a high-volume interventional center), robotic surgery (HMC has deployed da Vinci systems), neonatal and pediatric devices at Sidra Medicine, and AI-enhanced diagnostic imaging as Qatar upgrades radiology infrastructure post-2022. Diabetes care devices are growing with Qatar's ~17% adult diabetes prevalence.

Medical devices in Qatar require Ministry of Public Health (MOPH) registration. Qatar follows a risk-based registration framework aligned with GHTF standards. CE-marked or FDA-cleared devices benefit from expedited review pathways. MOPH registration timelines range from 3–12 months for Class I–II devices and 6–18 months for higher-risk Class III devices. BioNixus tracks MOPH Qatar registration timelines and HMC formulary listing decisions across device categories.

Qatar's National Health Strategy 2018–2022 (extended to 2030) commits USD 18+ billion to healthcare infrastructure. Key device-demand drivers include: expansion of Hamad General Hospital and the Women's Hospital; Sidra Medicine's clinical program deepening; the Qatar National Cancer Strategy targeting diagnosis, treatment, and survivorship capacity; and the National Diabetes and Endocrine Center expansion. Qatar is also piloting a formal HTA evaluation framework modelled on NICE — clinical evidence requirements are rising.

BioNixus delivers longitudinal hospital consumption analogue analytics, payer and formulary committee qualitative boards, bilingual HCP trackers where relevant, tender and access intelligence aligned to MOPH registration, HMC formulary processes, and sovereign procurement cadence in Qatar, KOL mapping, and adoption modelling for healthcare and life sciences. Teams receive decision-ready outputs cross-validated against EphMRA and BHBIA governance with GDPR-aligned multinational fieldwork coordinated from London and regional hubs.